Literature DB >> 31603409

2019 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guideline: Management of castration-resistant prostate cancer (CRPC).

Fred Saad1, Armen Aprikian2, Antonio Finelli3, Neil E Fleshner3, Martin Gleave4, Anil Kapoor5, Tamim Niazi6, Scott A North7, Frederic Pouliot8, Ricardo A Rendon9, Bobby Shayegan5, Srikala S Sridhar10, Alan So4, Nawaid Usmani11, Eric Vigneault12, Kim N Chi13.   

Abstract

Entities:  

Year:  2019        PMID： 31603409      PMCID： PMC6788916          DOI： 10.5489/cuaj.6136

Source DB:  PubMed          Journal:  Can Urol Assoc J        ISSN： 1911-6470            Impact factor:   1.862


× No keyword cloud information.
  30 in total

1.  Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial.

Authors:  Fred Saad; David Cella; Ethan Basch; Boris A Hadaschik; Paul N Mainwaring; Stéphane Oudard; Julie N Graff; Kelly McQuarrie; Susan Li; Stacie Hudgens; Joe Lawson; Angela Lopez-Gitlitz; Margaret K Yu; Matthew R Smith; Eric J Small
Journal:  Lancet Oncol       Date:  2018-09-10       Impact factor: 41.316

2.  Phase III Study Comparing a Reduced Dose of Cabazitaxel (20 mg/m2) and the Currently Approved Dose (25 mg/m2) in Postdocetaxel Patients With Metastatic Castration-Resistant Prostate Cancer-PROSELICA.

Authors:  Mario Eisenberger; Anne-Claire Hardy-Bessard; Choung Soo Kim; Lajos Géczi; Daniel Ford; Loïc Mourey; Joan Carles; Phillip Parente; Albert Font; Gabriel Kacso; Mustapha Chadjaa; Wenping Zhang; John Bernard; Johann de Bono
Journal:  J Clin Oncol       Date:  2017-08-15       Impact factor: 44.544

3.  Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial.

Authors:  Matthew Smith; Chris Parker; Fred Saad; Kurt Miller; Bertrand Tombal; Quan Sing Ng; Martin Boegemann; Vsevolod Matveev; Josep Maria Piulats; Luis Eduardo Zucca; Oleg Karyakin; Go Kimura; Nobuaki Matsubara; William Carlos Nahas; Franco Nolè; Eli Rosenbaum; Axel Heidenreich; Yoshiyuki Kakehi; Amily Zhang; Heiko Krissel; Michael Teufel; Junwu Shen; Volker Wagner; Celestia Higano
Journal:  Lancet Oncol       Date:  2019-02-06       Impact factor: 41.316

4.  Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer.

Authors:  Maha Hussain; Karim Fizazi; Fred Saad; Per Rathenborg; Neal Shore; Ubirajara Ferreira; Petro Ivashchenko; Eren Demirhan; Katharina Modelska; Andrew Krivoshik; Cora N Sternberg
Journal:  N Engl J Med       Date:  2018-06-28       Impact factor: 91.245

5.  Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study.

Authors:  Karim Fizazi; Michael Carducci; Matthew Smith; Ronaldo Damião; Janet Brown; Lawrence Karsh; Piotr Milecki; Neal Shore; Michael Rader; Huei Wang; Qi Jiang; Sylvia Tadros; Roger Dansey; Carsten Goessl
Journal:  Lancet       Date:  2011-02-25       Impact factor: 79.321

6.  Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study.

Authors:  Charles J Ryan; Matthew R Smith; Karim Fizazi; Fred Saad; Peter F A Mulders; Cora N Sternberg; Kurt Miller; Christopher J Logothetis; Neal D Shore; Eric J Small; Joan Carles; Thomas W Flaig; Mary-Ellen Taplin; Celestia S Higano; Paul de Souza; Johann S de Bono; Thomas W Griffin; Peter De Porre; Margaret K Yu; Youn C Park; Jinhui Li; Thian Kheoh; Vahid Naini; Arturo Molina; Dana E Rathkopf
Journal:  Lancet Oncol       Date:  2015-01-16       Impact factor: 41.316

7.  Abiraterone in metastatic prostate cancer without previous chemotherapy.

Authors:  Charles J Ryan; Matthew R Smith; Johann S de Bono; Arturo Molina; Christopher J Logothetis; Paul de Souza; Karim Fizazi; Paul Mainwaring; Josep M Piulats; Siobhan Ng; Joan Carles; Peter F A Mulders; Ethan Basch; Eric J Small; Fred Saad; Dirk Schrijvers; Hendrik Van Poppel; Som D Mukherjee; Henrik Suttmann; Winald R Gerritsen; Thomas W Flaig; Daniel J George; Evan Y Yu; Eleni Efstathiou; Allan Pantuck; Eric Winquist; Celestia S Higano; Mary-Ellen Taplin; Youn Park; Thian Kheoh; Thomas Griffin; Howard I Scher; Dana E Rathkopf
Journal:  N Engl J Med       Date:  2012-12-10       Impact factor: 91.245

8.  Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer.

Authors:  Matthew R Smith; James Eastham; Donald M Gleason; Daniel Shasha; Simon Tchekmedyian; Norman Zinner
Journal:  J Urol       Date:  2003-06       Impact factor: 7.450

9.  Alpha emitter radium-223 and survival in metastatic prostate cancer.

Authors:  C Parker; S Nilsson; D Heinrich; S I Helle; J M O'Sullivan; S D Fosså; A Chodacki; P Wiechno; J Logue; M Seke; A Widmark; D C Johannessen; P Hoskin; D Bottomley; N D James; A Solberg; I Syndikus; J Kliment; S Wedel; S Boehmer; M Dall'Oglio; L Franzén; R Coleman; N J Vogelzang; C G O'Bryan-Tear; K Staudacher; J Garcia-Vargas; M Shan; Ø S Bruland; O Sartor
Journal:  N Engl J Med       Date:  2013-07-18       Impact factor: 91.245

Review 10.  Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies.

Authors:  Terrence H Diamond; Celestia S Higano; Matthew R Smith; Theresa A Guise; Frederick R Singer
Journal:  Cancer       Date:  2004-03-01       Impact factor: 6.860
View more
  5 in total

1.  Canadian Urological Association best practice report: Bone health in prostate cancer.

Authors:  Luke T Lavallée; Ryan McLarty; Christopher Tran; Rodney H Breau; Patrick Richard; Bobby Shayegan; Brita Danielson; Marie-Paul Jammal; Fred Saad
Journal:  Can Urol Assoc J       Date:  2021-12       Impact factor: 1.862

Review 2.  Treatment of nonmetastatic castration-resistant prostate cancer: focus on second-generation androgen receptor inhibitors.

Authors:  Fred Saad; Martin Bögemann; Kazuhiro Suzuki; Neal Shore
Journal:  Prostate Cancer Prostatic Dis       Date:  2021-02-08       Impact factor: 5.455

3.  Distinct DNA methylation patterns associated with treatment resistance in metastatic castration resistant prostate cancer.

Authors:  Madonna R Peter; Misha Bilenky; Alastair Davies; Ruth Isserlin; Gary D Bader; Neil E Fleshner; Martin Hirst; Amina Zoubeidi; Bharati Bapat
Journal:  Sci Rep       Date:  2021-03-23       Impact factor: 4.379

4.  Evaluation of the reporting quality of clinical practice guidelines on prostate cancer using the RIGHT checklist.

Authors:  Kefeng Liu; Yanfang Ma; Yongjie Yang; Jingli Lu; Jie Zhao; Shuzhang Du; Xuepei Zhang; Chunlei Liu; Francesco Del Giudice; Masaki Shiota; Shingo Hatakeyama; Xiaojian Zhang; Jian Kang
Journal:  Ann Transl Med       Date:  2021-07

5.  CRPC Membrane-Camouflaged, Biomimetic Nanosystem for Overcoming Castration-Resistant Prostate Cancer by Cellular Vehicle-Aided Tumor Targeting.

Authors:  Kai Lu; Zheng Li; Qiang Hu; Jianfei Sun; Ming Chen
Journal:  Int J Mol Sci       Date:  2022-03-26       Impact factor: 5.923
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.